Clinical Case: An 85-year-old woman with neovascular AMD (OD) was treated with brolucizumab. After the second injection, she presented severe visual loss (BCVA (OD) of 0.3 to 0.01), intense vitritis, and vasculitis with retinal artery occlusion. Treatment with systemic and topical corticosteroids and laser panphotocoagulation was initiated, achieving stability of the condition.

Discussion: Brolucizumab-induced retinal vasculitis is a rare but severe complication, likely immune-mediated. Early detection is crucial to prevent irreversible damage. This case highlights the need for strict monitoring and immediate management of inflammatory signs, emphasizing the importance of pharmacovigilance in advanced anti-VEGF treatments.